CORDRAN (flurandrenolide) by Molecular Devices is corticosteroid hormone receptor agonists [moa]. Approved for corticosteroid [epc]. First approved in 1965.
Drug data last refreshed 1h ago · AI intelligence enriched 6d ago
CORDRAN (flurandrenolide) is a topical corticosteroid ointment approved in 1965 for inflammatory and pruritic dermatologic conditions. It works by stabilizing cellular and lysosomal membranes to reduce inflammation, itching, and vasodilation. The drug is absorbed through intact skin and metabolized hepatically before renal excretion.
As a mature LOE-approaching product with $3M in annual spending and high competitive pressure (score 30), the brand team is likely small and focused on retention rather than growth initiatives.
Corticosteroid Hormone Receptor Agonists
Corticosteroid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
CORDRAN roles are limited and focused on legacy product management, market defense, and compliance rather than innovation or growth. Career progression opportunities are constrained by the product's mature, declining lifecycle and minimal new business development activity.
Worked on CORDRAN at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo